DOCSLIB.ORG

Cervical Cancer Screening Learning Module

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cervical Cancer Screening Learning Module Cervical Cancer Screening Learning Module F O R H E A L T H C A R E P R O V I D E R S INITIATE LEARNING AND COMPETENCY TO PERFORM CERVICAL CANCER SCREENING MENTOR COLLEAGUES TO BECOME COMPETENT IN SCREENING REVIEW CURRENT RESEARCH AND TRENDS IN CERVICAL CANCER SCREENING cancercare.mb.ca/screening/hcp 1-855-95-CHECK X-PTLM Cervical Cancer Screening Learning Module for Health Care Providers Legal Disclaimer and Terms of Use The information in this Module is public information and should not be used as a substitute for any kind of professional medical advice, diagnosis or treatment. All copyrights are reserved by CervixCheck, CancerCare Manitoba (herein referred to as CervixCheck). No part of the Module may be reproduced, distributed or transmitted in any form or by any means, or stored in a database or retrieval system, without the prior written consent of the Program Manager, CervixCheck, unless such reproduction, transmission or storage is solely for the purpose of using the Module for personal use only. For information regarding permission, please contact CervixCheck. CervixCheck makes no representations or warranties in relation to the contents of the Module. While CervixCheck strives for accuracy, it is possible that the information in the Module may contain errors and omissions. CervixCheck reserves the right to review, update and/or amend the Module, from time to time, in its sole discretion, without recourse from any user of the Module. All references to the Module herein shall include any amended Module. Contact Person Education & Prevention Lead CancerCare Manitoba Prevention & Screening Unit 5 – 25 Sherbrook St., Winnipeg, Manitoba R3C 2B1 Phone: 1-855-95-CHECK Email: [email protected] Website: cancercare.mb.ca/screening/hcp CREATED: JUNE 2009 LAST UPDATED: FEBRUARY 2021 CERVICAL CANCER SCREENING cancercare.mb.ca/screening/hcp LEGAL DISCLAIMER- 1 LEARNING MODULE FOR HEALTHCARE PROVIDERS Acknowledgements Permission has been given to reproduce in part or whole, sections of the Alberta Cervical Cancer Screening Program (ACCSP) Registered Nurse Pap Smear Learning Module. Thank you to the ACCSP for permission to use this module as a guide for our work. CervixCheck, CancerCare Manitoba (CervixCheck) would like to acknowledge the following health care providers who contributed to the development and review of this learning module: Connie Beaton Primary Care Nurse Youth/Women’s Team NOR-MAN RHA Lorraine Cameron-Munro Registered Nurse, Nine Circles Community Health Centre Carolyn Clarke Women’s Health Clinic Practitioner, Women’s Health Clinic Alain Demers Team Leader, Department of Epidemiology, CancerCare Manitoba Dr. Mike Dillon Medical Director, Klinic Community Health Centre Elsie Duff Nurse Practitioner, Selkirk Teen Clinic, Interlake RHA Kim Froese Registered Nurse, Mount Carmel Clinic Lisa Goss Reproductive Health Nurse Coordinator, Klinic Diane Gudmundson Nurse Practitioner, Teen Clinic, Central RHA Wendy Kowaluk-Crozier Clinical Resource Nurse, Kildonan Medical Centre Cynthia Lathlin Aboriginal Liason Worker, Burntwood Community Health Resource Centre Dr. William Libich Medical Officer of Health, WRHA, Family Physician, Klinic Dr. Robert Lotocki Medical Director, CervixCheck, CancerCare Manitoba Jo-Anne Lutz Program Manager, Public Health, Burntwood RHA Sandy May Nurse Practitioner, North Eastman Health Association Lea Mutch Registered Nurse, Aboriginal Health and Wellness Louise Rawluk Nurse Practitioner, Burntwood Community Health Resource Centre Candice Rookes Director of Wellness, Aboriginal Health and Wellness Centre Trish Sattleberger Regional Educator, Staff Education, NOR-MAN RHA Brenna Shearer Program Manager, CervixCheck, CancerCare Manitoba Glenda Short Executive Director, Allied Health Services, Assiniboine RHA Kimberly Templeton Recruitment and Health Promotion Specialist, CervixCheck Donalda Wotton Community Care Analyst, WRHA A special thank you to Lisa Goss, Reproductive Health Nurse Coordinator, Klinic Community Health Centre, for her enthusiasm and generous contributions to the development of this learning module. CervixCheck would like to acknowledge Klinic Community Health Centre for their generous resources and support in the development of this module. CERVICAL CANCER SCREENING LEARNING MODULE FOR cancercare.mb.ca/screening/hcp HEALTHCARE PROVIDERS - iii - Endorsements The Pap Test Learning Module for Healthcare Providers has been endorsed by the following organizations: • College of Midwives of Manitoba • The College of Physicians and Surgeons of Manitoba • The Manitoba College of Family Physicians* • The University of Manitoba Department of Obstetrics, Gynecology and Reproductive Sciences • The University of Manitoba Division of Gynecologic Oncology CERVICAL CANCER SCREENING LEARNING MODULE FOR cancercare.mb.ca/screening/hcp HEALTHCARE PROVIDERS - iv - Table of Contents 1. Introduction • Target Audience & Purpose • Client-Centered Service • Learning Objectives • Competency Requirements • Competency Requirements Summary Table • Obtaining a CervixCheck Provider Number • Scope of Practice for those who can Perform Pap Tests • Professional Responsibility & Accountability • Medicolegal Issues Cervical Cancer Screening Learning Module Pre-Test 2. Disease Burden and Cervical Cancer Screening in Manitoba • Cervical Cancer • HPV Disease Burden • Natural History • Risk Factors for HPV and Cervical Cancer • Organized Cervical Cancer Screening in Manitoba: CervixCheck, CancerCare Manitoba 3. Cervical Cancer Screening Guidelines • Who Should Have a Pap Test and How Frequently? o Screening initiation o Screening interval o Screening cessation o Individuals who have never been sexually active o Clients who have had the HPV vaccine o Clients who are pregnant o Clients who have had a hysterectomy o Lesbian clients or women who have sex with women o The transgender client o Clients who require increased surveillance CERVICAL CANCER SCREENING LEARNING MODULE FOR cancercare.mb.ca/screening/hcp TABLE OF CONTENTS- 1 HEALTHCARE PROVIDERS o Clients who have had previous high grade cytology results • Key Messages for Health Care Providers • Benefits & Harms of Cervical Screening: Facilitating Informed Decision-Making 4. Counseling and Education • Before the Exam • During the Exam • After the Exam 5. Facilitating an Inclusive Environment • Barriers to Access • Lesbian Clients, WSW and Transgender People • Clients with a History of Sexual Abuse • Vaginismus • Clients with Disabilities • Clients with Diverse Language and Cultural Considerations • Female Genital Cutting (FGC) 6. Physiology, Anatomy, Abnormal Findings • Developmental Changes in the External and Internal Genitalia • External Genitalia • Internal Genitalia • The Cervix • Identifying Abnormal and Normal Cervical Appearances • Female Genital Cutting • Normal versus Abnormal Uterine Bleeding • Summary Chart of Genital Discharges, Infections, Ulcers and Lesions 7. Health History • Sexual and Reproductive Health History Review • Review of Related History CERVICAL CANCER SCREENING LEARNING MODULE FOR cancercare.mb.ca/screening/hcp TABLE OF CONTENTS- 2 HEALTHCARE PROVIDERS 8. External & Speculum Exam • Exam Equipment • Preparing the Client • External Examination • Speculum Exam Procedure • Special Considerations 9. The Papanicolaou Test • Ideal Conditions for Taking Pap Tests • Liquid Based Cytology • The Pap Test Procedure: Liquid Based Cytology • The Vaginal Vault Procedure: Liquid Based Cytology • How to Document a Pap Test • Cervical Cytology Request and Colposcopy Report Forms • CervixCheck Provider Number 10. Cervical Cancer Screening Test Results • The Bethesda System • Specimen Adequacy • Unsatisfactory for Evaluation • Satisfactory for Evaluation • Management of Cytology Results • Other Results • Limitations of Pap Test Results • Talking to Clients about Abnormal Pap Test Results • Colposcopy 11. New Technologies • The HPV Vaccines • HPV Testing CERVICAL CANCER SCREENING LEARNING MODULE FOR cancercare.mb.ca/screening/hcp TABLE OF CONTENTS- 3 HEALTHCARE PROVIDERS 12. Pap Test Access • Increasing Access to Cervical Cancer Screening Services: The Pap Test Clinic • Preparing for a Pap Test Clinic Cervical Cancer Screening Learning Module Post-Test Glossary Appendices 1. Education a. Cervical Cancer Screening Learning Module Videos b. Pap Test Procedure Sampling Technique c. Resources & Tools 2. Forms a. Screening History Request b. Cytology Requisition c. Colposcopy Report d. CervixCheck Provider Number Request Form 3. Assessment Tools a. Pre & Post Test Answer Key b. Performance Criteria Checklist for Preceptor 4. Case Studies CERVICAL CANCER SCREENING LEARNING MODULE FOR cancercare.mb.ca/screening/hcp TABLE OF CONTENTS- 4 HEALTHCARE PROVIDERS Chapter 1: Introduction Welcome to the CervixCheck, CancerCare Manitoba’s Cervical Cancer Screening Learning Module for Health Care Providers (HCPs). This module has been developed in consultation with Manitoba stakeholders in cervical cancer screening. It has been adapted with permission from the Alberta Cervical Cancer Screening Programs (ACCSP) Registered Nurse Pap Smear Learning Module. The Cervical Cancer Screening Learning Module can be found at: cancercare.mb.ca/screening/hcp Target Audience and Purpose The Cervical Cancer Screening Learning Module is for physicians, registered nurses, advanced practice nurses, licensed practical nurses, registered midwives, clinical assistants and/or physician assistants in Manitoba seeking to: • Initiate learning about cervical cancer and competency to perform
Load more

Recommended publications
  • A Study on Cervical Screening by PAP Smear and Correlation with Microbiological and Clinical Finding
    International Journal of Health and Clinical Research, 2021;4(5):280-283 e-ISSN: 2590-3241, p-ISSN: 2590-325X ____________________________________________________________________________________________________________________________________________ Original Research Article A study on cervical screening by PAP smear and correlation with microbiological and clinical finding Sona Goyal1, Manish Kumar Singhal2*,Kamlesh Yadav3, Rachna Agrawal4, Neil Sharma 5 1Consultant Pathologist, Department of Pathology, NIA , Jaipur, Rajasthan, India 2Associate Professor, Department of Pathology, Govt Medical college, Bhartapur, Rajasthan, India 3Professor, Department of Pathology, SMS Medical college Jaipur, Rajasthan, India 4Assistant Professor, Department of Anatomy, Govt Medical college , Bhartapur, Rajasthan, India 5Assistant Professor, Department of Pathology, Govt Medical college, Bhartapur, Rajasthan, India Received: 03-01-2021 / Revised: 08-02-2021 / Accepted: 25-02-2021 Abstract Introduction: Cervical cancer is one of the most common cause in India with over 75% of incidence and mortality. The objective of cervical cancer screening, therefore, is the detection of these lesions before developing into invasive cervical cancer.Methods: This prospective study was carried out over 2 year at the Department of Obstetrics and Gynaecology in National Institute of Ayurveda, Jaipur. Pap smears were collected from 400 sexually active women who were more than 21 years of age.Result: Most common findings were Inflammatory lesion (46.5%), followed by NILM(30%). Atrophic smear was seen in 16 cases (4%), rest had abnormal cellular changes in the form of ASCUS (1.25 %), LSIL (2 %) and Carcinoma (1%).Conclusion : Inflammatory smear is most common cytological finding in premenopausal age group . Epithelial cell abnormality is most common finding in premenopausal and postmenopausal age groups. Pap smear examination can be coupled with culture and sensitivity of vaginal swab to provide adequate treatment.
    [Show full text]
  • Developmental Abnormalities Easy to Misdiagnose
    8 Gynecology O B .GYN. NEWS • March 15, 2005 Developmental Abnormalities Easy to Misdiagnose BY JANE SALODOF MACNEIL inappropriate surgery, according to Dr. even an entity called obstructed hemi- Abnormalities of the vulva include con- Contributing Writer Zurawin, chief of the section of pediatric vagina.” genital labial fusion, which he said could and adolescent gynecology at Baylor and Clitoral hypertrophy is the only devel- be corrected with a simple flap proce- H OUSTON — Developmental abnor- of the gynecology service at Texas Chil- opmental abnormality of the clitoris, ac- dure. Surgery is rarely used, however, for malities of the vulva and vagina are often dren’s Hospital in Houston. cording to Dr. Zurawin. It used to be acquired labial agglutination. “This is one easy to correct, but also easy to misdiag- “You need to be familiar with the syn- treated by clitoridectomy with “very un- of most common referrals from pediatri- nose, Robert K. Zurawin, M.D., warned at dromes before you treat. Many people satisfactory results,” he said, describing cians, because they don’t know what to do a conference on vulvovaginal diseases are confronted with these conditions, and more conservative procedures in use to- with it and they are afraid,” Dr. Zurawin sponsored by Baylor College of Medicine. they don’t know what they really are,” he day. “This is mainly a cosmetic problem said. Many physicians have not been trained said. “With the obstructions, for example, for patients, and the surgical management He attributed most cases to diaper rash, to recognize these rare disorders and, as a they may just think it is an imperforate hy- is resection of the enlarged clitoris,” he bubble baths, and detergents that can in- result, run the risk of doing excessive or men and are not even aware that there is said.
    [Show full text]
  • Vaginal Screening After Hysterectomy in Australia
    CATEGORY: BEST PRACTICE Vaginal screening after hysterectomy in Australia Objectives: To provide advice on vaginal This statement has been developed and screening after hysterectomy. reviewed by the Women’s Health Committee and approved by the RANZCOG Target audience: Health professionals Board and Council. providing gynaecological care. A list of Women’s Health Committee Values: The evidence was reviewed by the Members can be found in Appendix A. Women’s Health Committee (RANZCOG), and applied to local factors relating to Disclosure statements have been received Australia. from all members of this committee. Background: This statement was first developed by Women’s Health Disclaimer This information is intended to Committee in November 2010 and provide general advice to practitioners. This reviewed in March 2020. information should not be relied on as a substitute for proper assessment with respect Funding: This statement was developed by to the particular circumstances of each RANZCOG and there are no relevant case and the needs of any patient. This financial disclosures. document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The document has been prepared having regard to general circumstances. First endorsed by RANZCOG: November 2010 Current: March 2020 Review due: March 2023 1 1. Introduction In December 2017, the National Cervical Screening Program in Australia changed from 2 yearly cervical cytology testing to 5 yearly primary HPV screening with reflex liquid-based cytology for those women in whom oncogenic HPV is detected in women aged 25–74 years. New Zealand has not yet transitioned to primary HPV screening.
    [Show full text]
  • 2021 – the Following CPT Codes Are Approved for Billing Through Women’S Way
    WHAT’S COVERED – 2021 Women’s Way CPT Code Medicare Part B Rate List Effective January 1, 2021 For questions, call the Women’s Way State Office 800-280-5512 or 701-328-2389 • CPT codes that are specifically not covered are 77061, 77062 and 87623 • Reimbursement for treatment services is not allowed. (See note on page 8). • CPT code 99201 has been removed from What’s Covered List • New CPT codes are in bold font. 2021 – The following CPT codes are approved for billing through Women’s Way. Description of Services CPT $ Rate Office Visits New patient; medically appropriate history/exam; straightforward decision making; 15-29 minutes 99202 72.19 New patient; medically appropriate history/exam; low level decision making; 30-44 minutes 99203 110.77 New patient; medically appropriate history/exam; moderate level decision making; 45-59 minutes 99204 165.36 New patient; medically appropriate history/exam; high level decision making; 60-74 minutes. 99205 218.21 Established patient; evaluation and management, may not require presence of physician; 99211 22.83 presenting problems are minimal Established patient; medically appropriate history/exam, straightforward decision making; 10-19 99212 55.88 minutes Established patient; medically appropriate history/exam, low level decision making; 20-29 minutes 99213 90.48 Established patient; medically appropriate history/exam, moderate level decision making; 30-39 99214 128.42 minutes Established patient; comprehensive history exam, high complex decision making; 40-54 minutes 99215 128.42 Initial comprehensive
    [Show full text]
  • Cervical Stenosis Causing Haematocervix and Haematometra in a Postmenopausal Woman Nicola English, Ellen Harker, Mathias Epee-Bekima
    Images in… BMJ Case Reports: first published as 10.1136/bcr-2016-217161 on 23 August 2016. Downloaded from Cervical stenosis causing haematocervix and haematometra in a postmenopausal woman Nicola English, Ellen Harker, Mathias Epee-Bekima King Edward Memorial DESCRIPTION Prior to the procedure she presented with wor- Hospital for Women Perth, A 73-year-old woman was referred to our gynaecol- sening suprapubic pain. She was febrile and tender Subiaco, Western Australia, Australia ogy clinic with a 2-week history of pelvic and suprapubically. An emergency EUA was performed vaginal pain. The pelvic ultrasound and CT scan with a presumptive diagnosis of an infected Correspondence to suggested a 10 cm haematometra and a 4 cm haematometra. Dr Nicola English, nicola. cervical cyst (figures 1–4). At time of surgery the initial cervical mass was [email protected] She had no history of postmenopausal bleeding found to be a large haematocervix with stenosis of Accepted 6 August 2016 and her most recent pap smear was normal. the external os. The cervix was incised and dilated The patient had been using tamoxifen for the which drained 800 mL of old blood from the previous 10 years for primary breast cancer. cervix and uterus. The underlying endometrium Examination revealed a large, mobile uterus and appeared normal on hysteroscopy. Histology was what appeared to be a cervical mass obscuring the also normal. cervical os. She was discharged home well on day 4 She was booked for an examination under anaes- postoperatively. thesia and hysteroscopy. http://casereports.bmj.com/ Figure 1 Pelvic ultrasound scan featuring a large haematometra.
    [Show full text]
  • Word You Cannot Say on Tv
    THE “V” WORD YOU CANNOT SAY ON TV SHELAGH LARSON, DNP, APRN WHNP, NCMP © Copyright 2020 Shelagh Larson Title Lorem Ipsum Dolor Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet 2017 2018 2019 Lorem ipsum dolor sit amet CELEBRITIES CAUGHT IN AWKWARD POSITIONS PARTS Vulva vagina is a specific internal structure, whereas the vulva is the whole external genitalia Gateway to the vagina is the seat for female sexual pleasure helps by flushing out the vulvovaginal fluids and usually maintains normal vaginal health Vestibule Secretions of fluid from the vestibule glands lubricate the vaginal orifice during sexual excitement. is the space between the labia minora and vagina Vagina The inside parts The hallway to the Uterus ◦ Vagina Dentata. Vagina Myths ◦ •Period Is Punishment ◦ •Hysteria ◦ •You Can’t Get Pregnant If It’s Legitimate Rape ◦ Sex With A Virgin Can Cure HIV/AIDS ◦ You can see someone's vagina if they go commando ◦ Douching after sex prevents pregnancy ◦ You can't get STDs from oral sex. ◦ You can lose something if inserted into the vagina ◦ You can't get pregnant if you have sex on your period The Vagina ◦ women of reproductive age, Lactobacillusis the predominant constituent of normal vaginal flora. ◦ Colonization by these bacteria keeps vaginal pH in the normal range (3.8 to 4.2), ◦ High estrogen levels maintain vaginal thickness, bolstering local defenses. ◦ Postmenopause a marked decrease in estrogen causes vaginal thinning, increasing vulnerability to infection and inflammation. ◦ Some treatments (eg, oophorectomy, birth
    [Show full text]
  • Female Genital Tract Done By
    Systemicist Pathology.. Lecture # 9& 10 Title : Female Genital Tract Done by: Dema Mhmd Khdier A man may die, nations may rise and fall…….But an idea lives on Vulva afeect all the linning of gt Some diseases can affect the vulva: 1)Vulvitis 2)Bartholin cyst :Obstruction of the excretory ducts of the gland 3)Dermatologic disorders 4) Non-specific epithelial disorders 5)Tumors Tumors & tumor like lesions Condyloma accuminatum : Hyperpigmented papules on genital skin OR Genital warts appear. caused by human papillomavirus (HPV) infection. 1) Condyloma accuminatum : 1)Usually multiple lesions 2)Associated with HPV 6 and HPV 11 Koilocytosis hollow. low grade 3) Not precancerous 4) May coexist with foci of (VIN grade I ) 2) Vulvar intraepithelial neoplasia (VIN) 1)Classic VIN Differentiated VIN _Young patients (40-60 y) _HPV associated _Usually multiple **low grade VIN (VINI) _HPV 6, 11 _NOT precancerous lesion _May coexist with conduloma accuminatum **High grade VIN: VIN II and VIN III (CIS) _HPV 16, 18 _May coexist with vaginal or cervical carcinoma. 2)Differentiated VIN _Older women > 60 y _NOT HPV associated _P53 mutation 3)Carcinoma of the vulva _3% of all genital tract cancers in women _Squamous cell carcinoma 95% _ Adenocarcinoma : 1-Bartholin gland CA 2 -Eccrine gland CA _ Extramammary paget disease _Melanoma _ Basal cell carcinoma (extremely rare Gross Appearance leukoplakia :white patch on a mucous membrane & associated with risk of cancer. Exophytic: describe solid organ lesions arising from the outer surface of the organ Most common on labia majora endophytic: grow inward into tissues in fingerlike projections from a superficial site of origin.
    [Show full text]
  • Colposcopy.Pdf
    CCololppooscoscoppyy ► Chris DeSimone, M.D. ► Gynecologic Oncology ► Images from Colposcopy Cervical Pathology, 3rd Ed., 1998 HistoHistorryy ► ColColpposcopyoscopy wwasas ppiioneeredoneered inin GGeermrmaanyny bbyy DrDr.. HinselmannHinselmann dduriurinngg tthhee 19201920’s’s ► HeHe sousougghtht ttoo prprooveve ththaatt micmicrroscopicoscopic eexaminxaminaationtion ofof thethe cervixcervix wouwoulldd detectdetect cervicalcervical ccancanceerr eeararlliierer tthhaann 44 ccmm ► HisHis workwork identidentiifiefiedd severalseveral atatyypicalpical appeappeararanancceses whwhicichh araree stistillll usedused ttooddaay:y: . Luekoplakia . Punctation . Felderung (mosaicism) Colposcopy Cervical Pathology 3rd Ed. 1998 HistoHistorryy ► ThrThrooughugh thethe 3030’s’s aanndd 4040’s’s brbreaeaktkthrhrouougghshs wwereere mamaddee regregaarrddinging whwhicichh aapppepeararancanceess wweerere moremore liklikelelyy toto prprogogressress toto invinvaasivesive ccaarcinomrcinomaa;; HHOOWEWEVVERER,, ► TheThessee ffiinndingsdings wweerere didifffficiculultt toto inteinterrpretpret sincesince theythey werweree notnot corcorrrelatedelated wwithith histologhistologyy ► OneOne resreseaearcrchherer wwouldould claclaiimm hhiiss ppatatientsients wwithith XX ffindindiingsngs nevernever hahadd ccaarcinomarcinoma whwhililee aannothotheerr emphemphaatiticcallyally belibelieevedved itit diddid ► WorldWorld wiwidede colposcopycolposcopy waswas uunnderderuutitillizizeedd asas aa diadiaggnosticnostic tooltool sseeconcondadaryry ttoo tthheseese discrepadiscrepannciescies HistoHistorryy
    [Show full text]
  • 2021 HEDIS Reference Guidefor Primary Care
    2021 HEDIS Reference Guide for Primary Care Cervical Cancer Screening (CCS) Patient Profile MVP members 21–64 years of age who have been screened for cervical cancer. Appropriate screening is defined by one of the following criteria: • Women 21–64 years of age who have a cervical cytology performed within the last three years (the measurement year and up to two years prior) • Women 30–64 years of age who have a cervical high-risk human papillomavirus (hrHPV) testing performed within the last five years (Note: Evidence of hrHPV testing within the last 5 years also captures patients who had cotesting; therefore additional methods to identify cotesting are not necessary.) • Women 30-64 years of age who had cervical cytology cotesting within the last five years Those excluded are women who have had a hysterectomy with no residual cervix (complete, total, or radical abdominal or vaginal hysterectomy), cervical agenesis, or acquired absence of cervix any time during the member's history through December 31 of the measurement year. How to Implement Best Practices and Improve Performance • Documentation in the medical record must include the name of the cervical screening, date of the test, and the result. This may be documented in an office note or a lab report, and can be submitted. • Cervical biopsies are not valid for primary cervical cancer screening and cannot be submitted. • When documenting medical/surgical history, avoid the use of “hysterectomy” alone, as this is not sufficient evidence that the cervix was removed. Be specific: “TAH”, TVH”, etc. • Documentation of “hysterectomy” alone in combination with documentation that the “patient no longer needs cervical cancer screening,” does meet criteria.
    [Show full text]
  • Diagnostic Tests for Vaginosis/Vaginitis
    Alberta Heritage Foundation for Medical Research Diagnostic tests for vaginosis/vaginitis Christa Harstall and Paula Corabian October 1998 HTA12 Diagnostic tests for vaginosis/vaginitis Christa Harstall and Paula Corabian October 1998 © Copyight Alberta Heritage Foundation for Medical Research, 1998 This Health Technology Assessment Report has been prepared on the basis of available information of which the Foundation is aware from public literature and expert opinion, and attempts to be current to the date of publication. The report has been externally reviewed. Additional information and comments relative to the Report are welcome, and should be sent to: Director, Health Technology Assessment Alberta Heritage Foundation for Medical Research 3125 Manulife Place, 10180 - 101 Street Edmonton Alberta T5J 3S4 CANADA Tel: 403-423-5727, Fax: 403-429-3509 This study is based, in part, on data provided by Alberta Health. The interpretation of the data in the report is that of the authors and does not necessarily represent the views of the Government of Alberta. ISBN 1-896956-15-7 Alberta's health technology assessment program has been established under the Health Research Collaboration Agreement between the Alberta Heritage Foundation for Medical Research and the Alberta Health Ministry. Acknowledgements The Alberta Heritage Foundation for Medical Research is most grateful to the following persons for their comments on the draft report and for provision of information. The views expressed in the final report are those of the Foundation. Dr. Jane Ballantine, Section of General Practice, Calgary Dr. Deirdre L. Church, Microbiology, Calgary Laboratory Services, Calgary Dr. Nestor N. Demianczuk, Royal Alexandra Hospital, Edmonton Dr.
    [Show full text]
  • Key Points: • a Pap Test and Pelvic Exam Are Important Parts of A
    Key Points: • A Pap test and pelvic exam are important parts of a woman’s routine health care because they can detect cancer or abnormalities that may lead to cancer of the cervix (see Question 3). • Women should have a Pap test at least once every three years, beginning about three years after they begin to have sexual intercourse, but no later than age 21 (see Question 6). • If the Pap test shows abnormalities, further tests an/or treatment may be necessary (see Question 11). • Human papillomavirus (HPV) infection is the primary risk factor for cervical cancer (see Question 13). 1. What is a Pap test? The Pap test (sometimes called a Pap smear) is a way to examine cells collected from the cervix (the lower, narrow end of the uterus). The main purpose of the Pap test is to find abnormal cell changes that may arise from cervical cancer or before cancer develops. 2. What is a pelvic exam? In a pelvic exam, the uterus, vagina, ovaries, fallopian tubes, bladder, and rectum are felt to find any abnormality in their shape or size. During a pelvic exam, an instrument called a speculum is used to widen the vagina so that the upper portion of the vagina and the cervix can be seen. 3. Why are a Pap test and pelvic exam important? A Pap test and pelvic exam are important parts of a woman’s routine health care because they can detect abnormalities that may lead to invasive cancer of the cervix. These abnormalities can be treated before cancer develops.
    [Show full text]
  • The Relationship Between Female Genital Aesthetic Perceptions and Gynecological Care
    Examining the Vulva: The Relationship between Female Genital Aesthetic Perceptions and Gynecological Care By Vanessa R. Schick B.A. May 2004, University of Massachusetts, Amherst A Dissertation Submitted to The Faculty of Columbian College of Arts and Sciences of The George Washington University in Partial Satisfaction of the Requirements for the Degree of Doctor of Philosophy January 31, 2010 Dissertation directed by Alyssa N. Zucker Associate Professor of Psychology and Women’s Studies The Columbian College of Arts and Sciences of The George Washington University certifies that Vanessa R. Schick has passed the Final Examination for the degree of Doctor of Philosophy as of August 19, 2009. This is the final and approved form of the dissertation. Examining the Vulva: The Relationship between Female Genital Aesthetic Perceptions and Gynecological Care Vanessa R. Schick Dissertation Research Committee: Alyssa N. Zucker, Associate Professor of Psychology & Women's Studies, Dissertation Director Laina Bay-Cheng, Assistant Professor of Social Work, University at Buffalo, Committee Member Maria-Cecilia Zea, Professor of Psychology, Committee Member ii © Copyright 2009 by Vanessa R. Schick All rights reserved iii Acknowledgments The past five years have changed me and my research path in ways that I could have never imagined. I feel incredibly fortunate for my mentors, colleagues, friends and family who have supported me throughout this journey. First, I would like to start by expressing my sincere appreciation to my phenomenal dissertation committee and all those who made this dissertation possible: Without Alyssa Zucker, my advisor, my journey would have been an entirely different one. Few advisors would allow their students to forge their own research path.
    [Show full text]